Number of people who experienced one or more falls · people with Parkinson's disease
Summary of findings for exercise plus education showed no clear difference in number of people who experienced one or more falls compared with control (low certainty).
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
It is very uncertain whether summary of findings for exercise plus education changes number of people sustaining one or more fall‐related fractures compared with control (very low certainty).
1 finding from 1 review
Quality of life immediately after the intervention · people with Parkinson's disease
1 finding from 1 review
Adverse events · people with Parkinson's disease
1 finding from 1 review
Economic outcomes · people with Parkinson's disease
1 finding from 1 review
Quality of life immediately after the intervention · people with Parkinson's disease
1 finding from 1 review
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Economic outcomes · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to lower rate of falls (falls per person‐year) compared with placebo (low certainty).
1 finding from 1 review
Number of people who experienced one or more falls · people with Parkinson's disease
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
1 finding from 1 review
Change in weight (kg) · People who have quit smoking
Nicotine replacement therapy for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (moderate certainty).
3 findings from 1 review
MD 0.52
21 studies · 2784 participants
Moderate
MD 0.08
11 studies · 1021 participants
Moderate
MD 0.37
17 studies · 1463 participants
Moderate
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether comparison 10: Provision of information and support changes repetition of SH at post‐intervention compared with TAU or another comparator (very low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficiency, costs or cost-effectiveness · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
1 finding from 1 review
Failure of therapy · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
It is very uncertain whether hall Technique (sealing with a preformed metal crown) changes failure of therapy compared with non-restorative cavity control (NRCC) (very low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review